Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

116.83USD
23 Jul 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$116.83
Open
$119.11
Day's High
$120.24
Day's Low
$115.97
Volume
61,487
Avg. Vol
79,406
52-wk High
$133.61
52-wk Low
$53.29

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Announces Formation Of Visen Pharmaceuticals
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA ANNOUNCES FORMATION OF VISEN PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE TRANSCON™ ENDOCRINOLOGY RARE DISEASE THERAPIES IN CHINA.ASCENDIS PHARMA A/S - ANNOUNCED FORMATION OF VISEN PHARMACEUTICALS, A JOINT VENTURE WITH AN INVESTOR SYNDICATE LED BY VIVO CAPITAL.ASCENDIS PHARMA A/S - 50/50 JOINT VENTURE WITH INVESTOR SYNDICATE LED BY VIVO CAPITAL.ASCENDIS PHARMA A/S - JOINT VENTURE TO DEVELOP, MANUFACTURE AND COMMERCIALIZE COMPANY'S ENDOCRINOLOGY RARE DISEASE THERAPIES IN GREATER CHINA.ASCENDIS PHARMA - INVESTOR SYNDICATE LED BY VIVO, ALONG WITH PARTICIPATION BY SOFINNOVA VENTURES, INVESTED $40 MILLION & RECEIVED 50 PERCENT OWNERSHIP OF VISEN.  Full Article

Ascendis Pharma Announces Orphan Drug Designation Granted For Transcon PTH As Treatment For Hypoparathyroidism
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED FOR TRANSCON PTH AS TREATMENT FOR HYPOPARATHYROIDISM.ASCENDIS PHARMA - U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO TRANSCON PTH, A LONG-ACTING PRODRUG OF PARATHYROID HORMONE.ASCENDIS PHARMA A/S - PLANS TO INITIATE A PHASE 3 PROGRAM FOR TRANSCON PTH IN Q1 OF 2019.  Full Article

Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP
Tuesday, 8 May 2018 

May 8 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP.ASCENDIS PHARMA A/S - ANTICIPATES TOP-LINE DATA FROM PHASE 1 TRIAL TO BE AVAILABLE IN Q4 OF 2018.  Full Article

Ascendis Pharma Reports Full Year 2017 Financial Results
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S REPORTS FULL YEAR 2017 FINANCIAL RESULTS.ASCENDIS PHARMA A/S - RARE DISEASE ENDOCRINOLOGY PIPELINE ADVANCES, WITH SIGNIFICANT MILESTONES ANTICIPATED OVER NEXT TWELVE MONTHS.ASCENDIS PHARMA A/S - AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF EUR 195.4 MILLION COMPARED TO EUR 180.3 MILLION AS OF DEC 31, 2016.  Full Article

Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.ASCENDIS PHARMA A/S - COMMENCED OFFERING OF $150 MILLION ADSS.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth
Tuesday, 26 Sep 2017 

Sept 26 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth.Ascendis Pharma A/S says ‍phase 1 trial evaluates single ascending doses and ten multiple daily doses of transcon pth​.  Full Article

Ascendis Pharma Q2 loss per share EUR 0.94
Friday, 18 Aug 2017 

Aug 18 (Reuters) - Ascendis Pharma A/S :Ascendis Pharma A/S reports second quarter 2017 financial results.Q2 loss per share EUR 0.94.Q2 earnings per share view EUR -0.73 -- Thomson Reuters I/B/E/S.Ascendis Pharma A/S - qtrly revenue EUR 444,000 versus EUR 1.1 million.  Full Article